Sun Pharma eyeing high single-digit top-line growth in current financial year

31 May 2022 Evaluate

Sun Pharmaceutical Industries is eyeing high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1626.80 -4.85 (-0.30%)
27-Jan-2026 13:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1626.80
Dr. Reddys Lab 1235.00
Cipla 1315.00
Zydus Lifesciences 887.85
Lupin 2127.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×